GSK
891 hedge funds and large institutions have $14.5B invested in GSK in 2025 Q2 according to their latest regulatory filings, with 110 funds opening new positions, 368 increasing their positions, 251 reducing their positions, and 62 closing their positions.
94% more call options, than puts
Call options by funds: $259M | Put options by funds: $133M
77% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 62
47% more repeat investments, than reductions
Existing positions increased: 368 | Existing positions reduced: 251
9.58% more ownership
Funds ownership: 8.87% → 18.45% (+9.6%)
4% more funds holding
Funds holding: 859 → 891 (+32)
2% more capital invested
Capital invested by funds: $14.2B → $14.5B (+$323M)
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$134M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$118M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$96.7M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$78.8M |
| 5 |
Primecap Management
Pasadena,
California
|
+$77.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$106M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$101M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$57.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$57.4M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$44.2M |
GSK Hedge Fund Activity: Q2 2025 in Review
891 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2025, worth a combined $14.5B — up 2.3% from $14.2B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new GSK positions and 62 closed out — a net gain of 48 holders — while 368 added to existing stakes and 251 trimmed.
The largest buyer was Federated Hermes, adding an estimated $134M. The largest seller was Goldman Sachs, cutting an estimated $106M.
- 891 institutional investors held GSK (GSK) as of Q2 2025, up from 859 in Q1 2025.
- Funds reported $14.5B of GSK stock for Q2 2025, up 2.3% quarter-over-quarter.
- 110 funds opened new GSK positions in Q2 2025 and 62 closed out, a net change of +48 holders.
- The largest GSK buyer in Q2 2025 was Federated Hermes, an estimated $134M added.
- The largest GSK seller in Q2 2025 was Goldman Sachs, an estimated $106M sold.
Based on aggregated 13F filings for Q2 2025.